

18.	Segment Data

On November 27, 2015, the Company completed the sale of the CMDS business to Guerbet. As a result, the CMDS business was eliminated from the Global Medical Imaging segment, which has been renamed Nuclear Imaging.

Prior year amounts have been recast to conform to current presentation.

The three reportable segments are further described below:


•	Specialty Brands produces and markets branded pharmaceutical and biopharmaceutical products and therapies;


•	Specialty Generics produces specialty generic pharmaceuticals and API consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and


•	Nuclear Imaging manufactures and markets radiopharmaceuticals (nuclear medicine).

Selected information by business segment was as follows:



	Three Months Ended
	December 25, 2015			December 26, 2014
Net sales:
Specialty Brands	$	543.2		$	373.6
Specialty Generics	257.6			284.2
Nuclear Imaging	103.6			101.9
Net sales of operating segments	904.4			759.7
Other ⁽¹⁾	10.4			8.5
Net sales	$	914.8		$	768.2
Operating income:
Specialty Brands	$	272.0		$	148.2
Specialty Generics	118.2			140.5
Nuclear Imaging	15.0			4.8
Segment operating income	405.2			293.5
Unallocated amounts:
Corporate and allocated expenses ⁽²⁾	(46.0		)	(39.8		)
Intangible asset amortization	(173.4		)	(124.8		)
Restructuring and related charges, net ⁽³⁾	(6.4		)	(7.3		)
Operating income	$	179.4		$	121.6


(1)	Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.


(2)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(3)	Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's segments are as follows:



	Three Months Ended
	December 25, 2015		December 26, 2014
Acthar	$	286.7	$	266.4
Inomax	110.8		—
Ofirmev	66.9		71.4
Therakos immunotherapy	50.4		—
Other	28.4		35.8
Specialty Brands	543.2		373.6

Hydrocodone (API) and hydrocodone-containing tablets	36.7		34.0
Oxycodone (API) and oxycodone-containing tablets	28.9		47.0
Methylphenidate ER	31.2		48.6
Other controlled substances	109.7		111.9
Other	51.1		42.7
Specialty Generics	257.6		284.2

Nuclear Imaging	103.6		101.9

Other⁽¹⁾	10.4		8.5
Net sales	$	914.8	$	768.2


(1)	Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.